GANYMED Pharmaceuticals AG

At GANYMED, we are dedicated to the delivery of a new class of highly effective truly cancer specific ideal monoclonal antibody therapeutics (iMAB) against solid cancers with high medical need.

In order to do this, we have brought together the strongest and most dynamic scientific team for translational medicine.

We have generated a sustainable pipeline of iMABs that we are developing as high value therapeutics for solid cancers with huge unmet clinical need, such as gastric, oesophageal, pancreatic, breast, colorectal, prostate and lung cancer.

Business building

Contact Information:

GANYMED Pharmaceuticals AG
Freiligrathstrasse 12
D-55131 Mainz

Phone:
Fax:
E-Mail:

+49 (0) 6131 / 1440 - 100
+49 (0) 6131 / 1440 - 114
info[at]ganymed-pharmaceuticals.com

[August 2010]

Clinical Phase I Results of GANYMED’s iMAB362 Antibody Demonstrate Excellent Safety

[April 2010]

ERNST & YOUNG, Deutscher Biotechnologie-Report 2010,

Das "Mainzer Modell": CI3

[Jan 2010]

34. Sendung TV-Magazin „in vivo“: vor Ort im Tumorvakzinationszentrum und bei Ganymed, Mainz (Deutsche Krebshilfe e. V.)

Meet us...

[September 2010]

European Cancer Cluster

Partnering, 15-17 sept. 2010,

(Folketeateret Oslo AS),

Oslo, Norway

[November 2010]

Bio-Europe 2010,

November 15-17, 2010

(International Congress Centre

Munich (ICM))

Ganymed belongs to CI3 - Cluster of

"individualized immunointervention -

ImmunoPolis"

Association for Cancer Immunotherapy

Biotechnologie-Industrie-Organisation Deutschland e.V.

Bio Deutschland e.V.

International Council for the Life Sciences